Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of Huperzine A Injection in Healthy Chinese Subjects
NCT06570655Phase 1Completed
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Huperzine A in Alzheimer's disease (AD), sponsored by Wanbangde Pharmaceutical Holding Group. Primary endpoints: Maximum blood concentration at Day 22, Area under the blood concentration-time curve from 0min to the time of last concentration at Day 22 and 1 more. Started May 2024; status: completed.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06570655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570655.